Abstract
Nicotinamide adenine dinucleotide (NAD+) biosynthesis from nicotinamide is used by mammalian cells to replenish their NAD+ stores and to avoid unwanted nicotinamide accumulation. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in this biosynthetic pathway, almost invariably leads to intracellular NAD+ depletion and, when protracted, to ATP shortage and cell demise. Cancer cells and activated immune cells express high levels of NAMPT and are highly susceptible to NAMPT inhibitors, as shown by the activity of these agents in models of malignant and inflammatory disorders. As the spectrum of conditions which could benefit from pharmacological NAMPT inhibition becomes broader, the mechanisms accounting for their activity are also eventually becoming apparent, including the induction of autophagy and the impairment of Ca2+- and NF-κB-dependent signaling. Here, we discuss the rationales for exploiting NAMPT inhibitors in cancer and inflammatory diseases and provide an overview of the preclinical and clinical studies in which these agents have been evaluated.
Keywords: NAD+, NAMPT, sirtuins, cancer, inflammation, cardiovascular disorders, chemotaxis, angiogenesis.
Current Drug Targets
Title:Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Volume: 14 Issue: 6
Author(s): By Fabrizio Montecucco, Michele Cea, Inga Bauer, Debora Soncini, Irene Caffa, Denise Lasiglie, Aimable Nahimana, Antonio Uccelli, Santina Bruzzone and Alessio Nencioni
Affiliation:
Keywords: NAD+, NAMPT, sirtuins, cancer, inflammation, cardiovascular disorders, chemotaxis, angiogenesis.
Abstract: Nicotinamide adenine dinucleotide (NAD+) biosynthesis from nicotinamide is used by mammalian cells to replenish their NAD+ stores and to avoid unwanted nicotinamide accumulation. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in this biosynthetic pathway, almost invariably leads to intracellular NAD+ depletion and, when protracted, to ATP shortage and cell demise. Cancer cells and activated immune cells express high levels of NAMPT and are highly susceptible to NAMPT inhibitors, as shown by the activity of these agents in models of malignant and inflammatory disorders. As the spectrum of conditions which could benefit from pharmacological NAMPT inhibition becomes broader, the mechanisms accounting for their activity are also eventually becoming apparent, including the induction of autophagy and the impairment of Ca2+- and NF-κB-dependent signaling. Here, we discuss the rationales for exploiting NAMPT inhibitors in cancer and inflammatory diseases and provide an overview of the preclinical and clinical studies in which these agents have been evaluated.
Export Options
About this article
Cite this article as:
Montecucco By Fabrizio, Cea Michele, Bauer Inga, Soncini Debora, Caffa Irene, Lasiglie Denise, Nahimana Aimable, Uccelli Antonio, Bruzzone Santina and Nencioni Alessio, Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060003
DOI https://dx.doi.org/10.2174/1389450111314060003 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation
Current Pharmaceutical Design Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Wharton’s Jelly or Bone Marrow Mesenchymal Stromal Cells Improve Cardiac Function Following Myocardial Infarction for More Than 32 Weeks in a Rat Model: A Preliminary Report
Current Stem Cell Research & Therapy Editorial (Thematic Issue: What's Behind the Sex Gap in Cardiovascular Mortality?)
Current Pharmaceutical Design HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Realising Heart Regeneration
Current Tissue Engineering (Discontinued) Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)
Current Gene Therapy The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Current Medicinal Chemistry New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Oxidative Stress and Cardiovascular Aging: Interaction Between NRF-2 and ADMA
Current Cardiology Reviews The Multifunctional Protein C System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Subject Index To Volume 2
Current Cardiology Reviews